Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections

Fondazione Policlinico Universitario Agostino Gemelli IRCCS144 enrolled

Overview

An observational two-center case-control study exploring the clinical impact of double-carbapenem use in a population of critically il patients with severe carbapenem-resistant Klebsiella pneumoniae infection

Study Type

OBSERVATIONAL

Enrollment

144

Conditions

Carbapenem Klebsiella Pneumonia

Interventions

none interventionOTHER

none intervention

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age ≥ 18 years; 2. ICU admission between November 2012 and December 2015; 3. documented CR-Kp invasive infection; 4. targeted antibiotic therapy lasting ≥ 72 hours Exclusion Criteria 1. Klebsiella infection, susceptible to carbapenems 2. Duration of antimicrobial therapy less than 72 hours 3. Data not completely available from the electronically medical chart

Outcomes

Primary Outcomes

28-day mortality

mortality after 28 day from infection

Time frame: 28 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.